Macrophage membrane-coated biomimetic magnetic nanoparticle loaded with interleukin 10 as potential candidate towards anti-atherosclerotic therapy: characterization and in vitro studies
Source abstract
Abstract
Atherosclerosis is the main cause of most cardiovascular events. At present, the drugs that have been approved for the treatment of atherosclerosis are mainly focused on lowering cholesterol/lipid levels, so their efficacy is limited. Preclinical data showed that the risk of atherosclerosis can be reduced by inhibiting inflammation. Interleukin (IL10) is an important anti-inflammatory factor in the genesis of atherosclerosis. In this research, IL10 was enveloped into β-cyclodextrin coupled with ferric oxide and then coated with macrophage membrane (MM/IL10-MNPs). The entrapment efficiency of IL10 was up to 95.2%, and it was a shell membrane structure that was observed by transmission electron microscopy. The particle size of MM/IL10-MNPs was 279.8 nm, as measured by dynamic light scattering. In vitro experiments showed that MM/IL10-MNPs had better sustained release ability than uncoated nanoparticles. Compared with free IL10 and IL10-MNPs, MM/IL10-MNPs also significantly inhibited the expression of nitric oxide, tumor necrosis factor-α, interleukin 1β, and interleukin 6. Cellular uptake assays showed that MM/IL10-MNPs had the effects of immune escape and targeted transport, which significantly increased the uptake of IL10 by inflammatory macrophages. These results confirmed the potential of MM/IL10-MNPs for targeted therapy in atherosclerosis.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Atherosclerosis and Cardiovascular Diseases · Immune cells in cancer · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Björkegren JLM, Lusis AJ (2022) Atherosclerosis: recent developments. Cell 185:1630–1645. https://doi.org/10.1016/j.cell.2022.04.00410.1016/j.cell.2022.04.004 ↗
2. Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17:1410–1422. https://doi.org/10.1038/nm.253810.1038/nm.2538 ↗
3. Moore KJ, Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145:341–355. https://doi.org/10.1016/j.cell.2011.04.00510.1016/j.cell.2011.04.005 ↗
4. Tabas I, Glass CK (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166–172. https://doi.org/10.1126/science.123072010.1126/science.1230720 ↗
5. Tabares-Guevara JH, Villa-Pulgarin JA, Hernandez JC (2021) Atherosclerosis: immunopathogenesis and strategies for immunotherapy. Immunotherapy 13:1231–1244. https://doi.org/10.2217/imt-2021-000910.2217/imt-2021-0009 ↗
6. Liu Y, Li D, Chen J et al (2006) Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 188:19–27. https://doi.org/10.1016/j.atherosclerosis.2005.10.02910.1016/j.atherosclerosis.2005.10.029 ↗
7. Xu S, Zhang J, Liu J et al (2021) The role of interleukin-10 family members in cardiovascular diseases. Int Immunopharmacol 94:107475. https://doi.org/10.1016/j.intimp.2021.10747510.1016/j.intimp.2021.107475 ↗
8. Mattos A, de Jager-Krikken A, de Haan M et al (2012) PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl4-induced fibrogenesis in mice. J Control Release 162:84–91. https://doi.org/10.1016/j.jconrel.2012.05.04110.1016/j.jconrel.2012.05.041 ↗
9. Li X, Ye M, Gao Y-E et al (2022) The systematic evaluation of physicochemical and biological properties in vitro and in vivo for natural silk fibroin nanoparticles. Adv Fiber Mater 4:1141–1152. https://doi.org/10.1007/s42765-022-00167-210.1007/s42765-022-00167-2 ↗
10. He H, Wu M, Zhu J et al (2022) Engineered spindles of little molecules around electrospun nanofibers for biphasic drug release. Adv Fiber Mater 4:305–317. https://doi.org/10.1007/s42765-021-00112-910.1007/s42765-021-00112-9 ↗
11. Wang C, Hou Y, Wang X et al (2022) Structural and interfacial effects on drug release kinetics of liquid-based fibrous catheter. Adv Fiber Mater 4:1645–1655. https://doi.org/10.1007/s42765-022-00201-310.1007/s42765-022-00201-3 ↗
12. Xu X, Yu H, Hang L et al (2014) Preparation of naringenin/ β -cyclodextrin complex and its more potent alleviative effect on choroidal neovascularization in rats. BioMed Res Int 2014:1–9. https://doi.org/10.1155/2014/62350910.1155/2014/623509 ↗
13. Luke DR, Tomaszewski K, Damle B, Schlamm HT (2010) Review of the basic and clinical pharmacology of sulfobutylether-β-cydodextrin (SBECD). J Pharm Sci 99:3291–3301. https://doi.org/10.1002/jps.2210910.1002/jps.22109 ↗
14. Talev J, Kanwar JR (2020) Iron oxide nanoparticles as imaging and therapeutic agents for atherosclerosis. Semin Thromb Hemost 46:553–562. https://doi.org/10.1055/s-0039-340024710.1055/s-0039-3400247 ↗
15. Goszczyński TM, Gawłowski M, Girek B et al (2017) Synthesis of β-cyclodextrin-lysozyme conjugates and their physicochemical and biochemical properties. J Incl Phenom Macrocycl Chem 87:341–348. https://doi.org/10.1007/s10847-017-0706-810.1007/s10847-017-0706-8 ↗
16. Tan S, Wu T, Zhang D, Zhang Z (2015) Cell or cell membrane-based drug delivery systems. Theranostics 5:863–881. https://doi.org/10.7150/thno.1185210.7150/thno.11852 ↗
17. Fang RH, Kroll AV, Gao W, Zhang L (2018) Cell membrane coating nanotechnology. Adv Mater 30:1706759. https://doi.org/10.1002/adma.20170675910.1002/adma.201706759 ↗
18. Parodi A, Quattrocchi N, van de Ven AL et al (2013) Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 8:61–68. https://doi.org/10.1038/nnano.2012.21210.1038/nnano.2012.212 ↗
19. Park JH, Dehaini D, Zhou J et al (2020) Biomimetic nanoparticle technology for cardiovascular disease detection and treatment. Nanoscale Horiz 5:25–42. https://doi.org/10.1039/C9NH00291J10.1039/C9NH00291J ↗
20. Wang Y, Zhang K, Li T et al (2021) Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications. Theranostics 11:164–180. https://doi.org/10.7150/thno.4784110.7150/thno.47841 ↗
21. Gao C, Huang Q, Liu C et al (2020) Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat Commun 11:2622. https://doi.org/10.1038/s41467-020-16439-710.1038/s41467-020-16439-7 ↗
22. Sudha N, Yousuf S, Israel EVMV et al (2016) On the accessibility of surface-bound drugs on magnetic nanoparticles. Encapsulation of drugs loaded on modified dextran-coated superparamagnetic iron oxide by β-cyclodextrin. Colloids Surf b Biointerfaces 141:423–428. https://doi.org/10.1016/j.colsurfb.2016.02.02010.1016/j.colsurfb.2016.02.020 ↗
23. Kim M, Sahu A, Hwang Y et al (2020) Targeted delivery of anti-inflammatory cytokine by nanocarrier reduces atherosclerosis in Apo E−/- mice. Biomaterials 226:119550. https://doi.org/10.1016/j.biomaterials.2019.11955010.1016/j.biomaterials.2019.119550 ↗
24. Guo H, Zhang Y, Liang W et al (2019) An inorganic magnetic fluorescent nanoprobe with favorable biocompatibility for dual-modality bioimaging and drug delivery. J Inorg Biochem 192:72–81. https://doi.org/10.1016/j.jinorgbio.2018.12.00210.1016/j.jinorgbio.2018.12.002 ↗
25. Zhang J, Zu Y, Dhanasekara CS et al (2018) Detection and treatment of atherosclerosis using nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(1):10.1002/wnan.1412. https://doi.org/10.1002/wnan.141210.1002/wnan.1412 ↗
26. Tang D, Wang Y, Wijaya A et al (2021) ROS-responsive biomimetic nanoparticles for potential application in targeted anti-atherosclerosis. Regen Biomater 8:rbab033. https://doi.org/10.1093/rb/rbab03310.1093/rb/rbab033 ↗
27. Yang L, Zang G, Li J et al (2020) Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives. Regen Biomater 7:349–358. https://doi.org/10.1093/rb/rbaa01910.1093/rb/rbaa019 ↗
28. Förstermann U, Xia N, Li H (2017) Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res 120:713–735. https://doi.org/10.1161/CIRCRESAHA.116.30932610.1161/CIRCRESAHA.116.309326 ↗
29. Tousoulis D, Kampoli A-M, Tentolouris Nikolaos Papageorgiou C, Stefanadis C (2012) The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10:4–18. https://doi.org/10.2174/15701611279882976010.2174/157016112798829760 ↗
30. Gimbrone MA, García-Cardeña G (2016) Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 118:620–636. https://doi.org/10.1161/CIRCRESAHA.115.30630110.1161/CIRCRESAHA.115.306301 ↗
31. Barua S, Mitragotri S (2014) Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today 9:223–243. https://doi.org/10.1016/j.nantod.2014.04.00810.1016/j.nantod.2014.04.008 ↗
32. Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951. https://doi.org/10.1038/nbt.333010.1038/nbt.3330 ↗
33. Cao H, Dan Z, He X et al (2016) Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 10:7738–7748. https://doi.org/10.1021/acsnano.6b0314810.1021/acsnano.6b03148 ↗
34. Poznyak AV, Bharadwaj D, Prasad G et al (2021) Anti-inflammatory therapy for atherosclerosis: focusing on cytokines. Int J Mol Sci 22:7061. https://doi.org/10.3390/ijms2213706110.3390/ijms22137061 ↗